Currently, the OlympiA trial [21], a multicenter phase III trial to compare the efficacy and safety of olaparib with placebo as adjuvant therapy in patients with high-risk early stage breast cancer with BRCA1/2 mutations and HER2-negative breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy is underway [21]. Here, BRCA1 is linked to breast carcinoma.